Eissa Sanaa, Matboli Marwa, Shehata Hanan H, Essawy Nada O E
Oncology Diagnostic Unit, Medical Biochemistry and Molecular biology Department, Faculty of Medicine, Ain Shams University, Abbassia, P.O. Box 11381, Cairo, Egypt,
Tumour Biol. 2015 Jun;36(6):4487-94. doi: 10.1007/s13277-015-3090-2. Epub 2015 Jan 18.
The aim of this study is to identify micro-ribonucleic acid (microRNA) and its target, in addition to their relationship to the outcome in breast cancer (BC). To achieve this aim, we investigated microRNA-10b (miR-10b) and minichromosome maintenance complex component 5 (MCM5 mRNA) expression in 230 breast tissue samples by real-time PCR and semiquantitative conventional RT-PCR, respectively. Relapse-free survival (RFS) associated with miRNA-10b and MCM5 mRNA were tested by Kaplan-Meier survival analysis. The impact of miRNA-10b andMCM5 mRNA expression on the survival was evaluated by Cox proportional hazard regression model. The expression of miRNA-10b and MCM5 mRNA was positive in 86.4 and 79.7 % breast cancer patients, respectively. The overall concordance rate between miRNA-10b and MCM5 RNA was 90.4 %. The median follow-up period was 50 months. The survival analysis showed that high levels of both miR-10b and MCM5 were associated with short relapse free survival of BC. We identified MCM5 mRNA expression changes consistent with the miRNA-10b target regulation. Thus, we could consider miRNA-10b and MCM5 mRNA as prognostic markers and potential therapeutic targets in breast cancer to be applied to other patient data sets.
本研究的目的是识别微小核糖核酸（microRNA）及其靶标，以及它们与乳腺癌（BC）预后的关系。为实现这一目的，我们分别通过实时PCR和半定量常规逆转录PCR，研究了230份乳腺组织样本中微小核糖核酸-10b（miR-10b）和微小染色体维持复合物组分5（MCM5 mRNA）的表达。通过Kaplan-Meier生存分析检测与miRNA-10b和MCM5 mRNA相关的无复发生存期（RFS）。通过Cox比例风险回归模型评估miRNA-10b和MCM5 mRNA表达对生存的影响。miRNA-10b和MCM5 mRNA在乳腺癌患者中的阳性表达率分别为86.4%和79.7%。miRNA-10b与MCM5 RNA的总体一致性率为90.4%。中位随访期为50个月。生存分析表明，miR-10b和MCM5的高水平均与BC患者较短的无复发生存期相关。我们发现MCM5 mRNA的表达变化与miRNA-10b的靶标调控一致。因此，我们可以将miRNA-10b和MCM5 mRNA视为乳腺癌的预后标志物和潜在治疗靶点，应用于其他患者数据集。
